The estimated Net Worth of John A Kraeutler is at least $11.7 Milion dollars as of 24 August 2017. John Kraeutler owns over 7,000 units of Meridian Bioscience stock worth over $11,727,463 and over the last 21 years John sold VIVO stock worth over $0.
John has made over 11 trades of the Meridian Bioscience stock since 2011, according to the Form 4 filled with the SEC. Most recently John bought 7,000 units of VIVO stock worth $95,690 on 24 August 2017.
The largest trade John's ever made was exercising 48,820 units of Meridian Bioscience stock on 12 September 2011 worth over $102,034. On average, John trades about 2,610 units every 33 days since 2003. As of 24 August 2017 John still owns at least 345,230 units of Meridian Bioscience stock.
You can see the complete history of John Kraeutler stock trades at the bottom of the page.
John's mailing address filed with the SEC is 3471 RIVER HILLS DRIVE, , CINCINNATI, OH, 45244.
Over the last 22 years, insiders at Meridian Bioscience have traded over $8,089,514 worth of Meridian Bioscience stock and bought 228,244 units worth $3,053,655 . The most active insiders traders include Richard Eberly, John P. Kenny a John A Kraeutler. On average, Meridian Bioscience executives and independent directors trade stock every 41 days with the average trade being worth of $424,761. The most recent stock trade was executed by James M. Anderson on 6 January 2023, trading 8,500 units of VIVO stock currently worth $173,230.
Meridian Bioscience Inc. is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.The company is dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, Meridian provides critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, Meridian provides diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. The company builds relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian Bioscience executives and other stock owners filed with the SEC include: